Stockscreener 앱 받기
10.82
23.23%
2.04
시간 외 거래:
10.00
-0.82
-7.58%
전일 마감가:
$8.78
열려 있는:
$12.2
하루 거래량:
18.82M
Relative Volume:
19.43
시가총액:
$473.87M
수익:
-
순이익/손실:
$-110.66M
주가수익비율:
-3.4945
EPS:
-3.0963
순현금흐름:
$-97.76M
1주 성능:
+30.83%
1개월 성능:
+57.27%
6개월 성능:
+236.02%
1년 성능:
+144.80%
1일 변동 폭
$10.40
$13.67
1주일 범위
$7.80
$13.67
52주 변동 폭
$1.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
10.82 | 384.53M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna Therapeutics (NASDAQ: KYTX) launches $100M stock sale with $15M underwriters’ option - Stock Titan
Kyverna Therapeutics stock price target raised to $33 from $25 at Morgan Stanley - Investing.com UK
Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks Making The Biggest Moves Today - Asianet Newsable
KYTX Stock Skyrockets: Investors Take Notice - timothysykes.com
Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks making the biggest moves today - MSN
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome (KYTX) - Seeking Alpha
Kyverna Therapeutics (NASDAQ:KYTX) Hits New 12-Month HighStill a Buy? - MarketBeat
Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial - Endpoints News
'Unprecedented' data prime Kyverna for 1st autoimmune CAR-T drug - Fierce Biotech
Kyverna Therapeutics Sees Unusually High Options Volume (NASDAQ:KYTX) - MarketBeat
Kyverna shares spike as CAR-T hits endpoints in stiff person syndrome - FirstWord Pharma
Kyverna Therapeutics announces topline data from registrational KYSA-8 trial - TipRanks
Can Kyverna Therapeutics Stock Surge Further? - StocksToTrade
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease - BioPharma Dive
Kyverna Therapeutics Inc. (KYTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Is Kyverna Therapeutics Stock Skyrocketing Monday?Kyverna Therapeutics (NASDAQ:KYTX) - Benzinga
Kyverna rises on stiff person syndrome data - pharmaphorum
Kyverna Reports Positive Phase 2 Trial Results - TipRanks
Kyverna shares jump on strong results from SPS clinical trial - MSN
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome? - Stocktwits
Kyverna Shares Surge on Strong Topline Results From Phase 2 SPS Trial - Tokenist
Kyverna Therapeutics stock soars after positive SPS trial data By Investing.com - Investing.com UK
Kyverna Therapeutics stock soars after positive SPS trial data - Investing.com
KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN
KYTX: Miv-cel achieved robust efficacy and safety in SPS, supporting a 2026 FDA submission - TradingView — Track All Markets
Kyverna Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Kyverna jumps after cell therapy meets main goal of mid-stage study - TradingView — Track All Markets
Kyverna's cell therapy meets main goal of mid-stage study - TradingView — Track All Markets
Kyverna Therapeutics shares surge 24% premarket after positive trial data - marketscreener.com
Kyverna Therapeutics Announces Positive Topline Data From Registrational Kysa-8 Trial Of Miv-Cel (Kyv-101) In Stiff Person Syndrome - TradingView — Track All Markets
Kyverna Therapeutics Announces Positive Topline Data from KYSA-8 Trial - TradingView — Track All Markets
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of ... - Bakersfield.com
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome - Yahoo Finance
Kyverna Therapeutics Inc Stock Analysis and ForecastSector Rotation Strategies & Free Stock Chart Pattern Guides - earlytimes.in
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Kyverna to present topline results from Phase 2 trial in stiff person syndrome - Investing.com
Kyverna Therapeutics to Present Topline Results from Phase 2 KYSA-8 Clinical Trial for KYV-101 in Stiff Person Syndrome - Quiver Quantitative
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome - The Manila Times
Kyverna Therapeutics to Report Topline Results from - GlobeNewswire
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Yahoo Finance
Momentum Shift: What is the fair value of Kyverna Therapeutics Inc stock now2025 Market Overview & Smart Swing Trading Alerts - moha.gov.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Morgan Stanley maintains Kyverna Therapeutics (KYTX) overweight recommendation - MSN
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley - TipRanks
Why analysts remain bullish on Kyverna Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-12-04 05:07:23 - Newser
How institutional buying supports Kyverna Therapeutics Inc. stock2025 Market Outlook & Risk Managed Investment Strategies - Newser
Kyverna Therapeutics (KYTX) Stock Analysis Report | Financials & Insights - Benzinga
IPO Launch: Will Kyverna Therapeutics Inc stock recover faster than peersJuly 2025 Momentum & AI Optimized Trade Strategies - BỘ NỘI VỤ
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):